Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

AI-assisted interpretation of Markush structures in pharmaceutical patents: a review of emerging tools, datasets, and challenges.

Created on 04 Apr 2026

Authors

Jennifer M Umbles Hayes, Emmanuel O Olawode, Anietie Andy, Edmund Essah Ameyaw

Published in

Journal of cheminformatics. Apr 03, 2026. Epub Apr 03, 2026.

Abstract

Automated interpretation of Markush structures widely used in pharmaceutical patents to claim large families of related compounds remains challenging due to non-machine-readable structure images, variable R-groups, dependency rules, scaffold diversity, and heterogeneous claim language. Challenges include attachment points and stereochemistry, nested/conditional dependencies, and inconsistent drafting conventions that hinder faithful enumeration. Early rule-based cheminformatics systems parsed claims and mapped Markush representations into searchable formats, but struggled with nested dependencies, cross-references, and multimodal (text + image) descriptions. More recently, artificial intelligence (AI) methods have been introduced including language-based tools, vision-based tools, and multimodal or hybrid tools. Language-based tools increasingly use large language models (LLMs) and natural language processing (NLP) capabilities to extract variable definitions, constraints, and dependency graphs from claim text; vision systems translate structure depictions into machine-readable formats (e.g., SMILES, CXSMILES); multimodal or hybrid pipelines align both for end-to-end interpretation. Emerging datasets support these efforts, though licensing, family-wise leakage, and standardized splits remain inconsistent. This narrative review synthesizes tools, datasets, and evaluation practices for AI-assisted Markush interpretation, identifies persistent failure modes, and maps open legal questions (sufficiency, enablement, enforceability). We outline priorities for the field; transparent benchmarks with family-aware splits, interpretable constraint handling, and workflows aligned with U.S. Patent Office practice, near-term use is decision support, not legal advice.

PMID:
41933423
Bibliographic data and abstract were imported from PubMed on 04 Apr 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 37
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement